Allogeneic transplantation of hematopoietic stem cells and solid organ in the same patient: an update

Abstract

Some recent data concern allo-HSCT carried out after SOT. The hematological relapse rate was 22 %, thus allowing long-term observations. The 5-year rate for the solid organ failure was about 30%, mostly, due to graft rejection.In summary, SOT can represent a valuable treatment strategy in HSCT recipients who develop an organ failure. Infections, graft rejection and other complications are frequent but usually manageable. Also, selected SOT recipients developing hematological disorders may benefit from allo-HSCT.